Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharma (NQ: AMPH )

37.57 +0.66 (+1.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 205,699
Open 36.71
Bid (Size) 37.30 (1)
Ask (Size) 37.75 (1)
Prev. Close 36.91
Today's Range 36.45 - 37.60
52wk Range 26.76 - 44.46
Shares Outstanding 47,896,820
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74
A Relative Strength Rating upgrade for BioMarin Pharmaceutical shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Exelixis Stock Generating Improved Relative Strength Rating
Exelixis stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 69 to 76. 
Via Investor's Business Daily

Performance

YTD
+33.23%
+33.23%
1 Month
+16.21%
+16.21%
3 Month
+32.38%
+32.38%
6 Month
+33.04%
+33.04%
1 Year
+3.10%
+3.10%

More News

Read More
Vertex Pharmaceuticals Stock Gets Technical Rating Upgrade
Via Investor's Business Daily
Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg
Via ACCESSWIRE
Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating
Via Investor's Business Daily
Why Shares of Amphastar Pharmaceuticals Rose Today
Via The Motley Fool
Earnings Outlook For Amphastar Pharmaceuticals
Via Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2022
Via ACCESSWIRE
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference
Via ACCESSWIRE
Can This Company's Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems?
Via Benzinga
Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022
Via ACCESSWIRE
Intercept Pharmaceutical Stock Sees RS Rating Rise To 91
Via Investor's Business Daily
Recursion Pharma Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark
Via Investor's Business Daily
7 Safe Stocks to Rely on When the Market Swerves
Via InvestorPlace
Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals's Return on Invested Capital Overview
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes
Via ACCESSWIRE
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review
Via Investor's Business Daily
Amphastar Pharmaceuticals: Q2 Earnings Insights
Via Benzinga
Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.